[go: up one dir, main page]

CU24766B1 - Péptidos lineales que inhiben la fosforilación mediada por ck2 - Google Patents

Péptidos lineales que inhiben la fosforilación mediada por ck2

Info

Publication number
CU24766B1
CU24766B1 CU2021000058A CU20210058A CU24766B1 CU 24766 B1 CU24766 B1 CU 24766B1 CU 2021000058 A CU2021000058 A CU 2021000058A CU 20210058 A CU20210058 A CU 20210058A CU 24766 B1 CU24766 B1 CU 24766B1
Authority
CU
Cuba
Prior art keywords
seq
peptides
inhibit
linear peptides
mediated phosphorylation
Prior art date
Application number
CU2021000058A
Other languages
English (en)
Other versions
CU20210058A7 (es
Inventor
Pérez Vladimir Armando Besada
Menéndez Evelin Caballero
Pérez Hilda Elisa Garay
Blanco Sonia González
López Luis Javier González
Nieto Gerardo Enrique Guillén
González Yordanka Masforrol
Rodríguez Silvio Ernesto Perea
Negrin Yasser Perera
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2021000058A priority Critical patent/CU24766B1/es
Priority to ARP220101768A priority patent/AR126388A1/es
Priority to KR1020247003121A priority patent/KR20240032882A/ko
Priority to MX2024000542A priority patent/MX2024000542A/es
Priority to PCT/CU2022/050007 priority patent/WO2023280330A1/es
Priority to AU2022308094A priority patent/AU2022308094A1/en
Priority to CA3225387A priority patent/CA3225387A1/en
Priority to US18/578,001 priority patent/US20240317827A1/en
Priority to EP22760645.6A priority patent/EP4368710A1/en
Priority to JP2024514574A priority patent/JP2024534231A/ja
Priority to CN202280055326.7A priority patent/CN117795064A/zh
Publication of CU20210058A7 publication Critical patent/CU20210058A7/es
Publication of CU24766B1 publication Critical patent/CU24766B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

<p>La presente invención se enmarca en el campo de la inmunología, biología molecular y el cáncer. Se refiere a péptidos lineales que inhiben la fosforilación mediada por la enzima Caseína Kinasa 2 (CK2), que poseen una secuencia de aminoácidos que se selecciona del grupo compuesto por las secuencias identificadas como SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50 Y SEQ ID NO:57 - SEQ ID NO:62, así como los polipéptidos que comprenden dichos péptidos y un péptido de penetración intracelular. Los péptidos referidos son aplicables en la industria farmacéutica para uso terapéutico en humanos.</p>
CU2021000058A 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2 CU24766B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
ARP220101768A AR126388A1 (es) 2021-07-09 2022-07-06 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden
KR1020247003121A KR20240032882A (ko) 2021-07-09 2022-07-07 Ck2-매개 인산화를 억제하는 선형 펩타이드 및 이를 포함하는 조성물
MX2024000542A MX2024000542A (es) 2021-07-09 2022-07-07 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden.
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden
AU2022308094A AU2022308094A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
CA3225387A CA3225387A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof
US18/578,001 US20240317827A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
EP22760645.6A EP4368710A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
JP2024514574A JP2024534231A (ja) 2021-07-09 2022-07-07 Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物
CN202280055326.7A CN117795064A (zh) 2021-07-09 2022-07-07 抑制由ck2介导的磷酸化的线性肽和包含其的组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2

Publications (2)

Publication Number Publication Date
CU20210058A7 CU20210058A7 (es) 2023-02-13
CU24766B1 true CU24766B1 (es) 2025-08-13

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2

Country Status (11)

Country Link
US (1) US20240317827A1 (es)
EP (1) EP4368710A1 (es)
JP (1) JP2024534231A (es)
KR (1) KR20240032882A (es)
CN (1) CN117795064A (es)
AR (1) AR126388A1 (es)
AU (1) AU2022308094A1 (es)
CA (1) CA3225387A1 (es)
CU (1) CU24766B1 (es)
MX (1) MX2024000542A (es)
WO (1) WO2023280330A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides

Also Published As

Publication number Publication date
CU20210058A7 (es) 2023-02-13
WO2023280330A1 (es) 2023-01-12
US20240317827A1 (en) 2024-09-26
EP4368710A1 (en) 2024-05-15
MX2024000542A (es) 2024-02-02
AR126388A1 (es) 2023-10-11
CN117795064A (zh) 2024-03-29
JP2024534231A (ja) 2024-09-18
KR20240032882A (ko) 2024-03-12
CA3225387A1 (en) 2023-01-12
AU2022308094A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2024015050A (es) L-asparaginasa modificada
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
EA201891127A1 (ru) Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью
EP3424524A3 (en) Cancer rna-vaccine
AR111207A1 (es) Anticuerpos anti-lag3
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
MX2019001905A (es) Peptido objetivo de tumor maligno.
EA201990856A1 (ru) Новые противомикробные агенты против бактерий enterococcus
CR20180008A (es) Variantes de il-37
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
CU24766B1 (es) Péptidos lineales que inhiben la fosforilación mediada por ck2
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
EA202190531A1 (ru) Коллекции пептидов, пептидные агенты и способы их применения
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
AR074388A1 (es) Un peptido inhibidor del factor de necrosis tumoral alfa, un proceso para la preparacion de dicho peptido y una composicion farmaceutica que comprende dicho peptido
MX2018002616A (es) Proteina de fusion.